NeuroSense Therapeutics
About NeuroSense Therapeutics
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in conducting a Phase 2b, double-blind, randomized, placebo controlled clinical study in ALS patients globally.
$NRSN
Find NeuroSense Therapeutics Execs' Valid Emails
Up to 90% verified emails and mobile numbers, refreshed weekly.
Company Details
0-500K
Biotechnology Research
11-50 employees
Public Company
Cambridge, Massachusetts
United States
Frequently Asked Questions about
What is NeuroSense Therapeutics's industry?
NeuroSense Therapeutics operates in the Biotechnology Research industry and is headquartered in United States.
How many employees does NeuroSense Therapeutics have?
NeuroSense Therapeutics has approximately 11-50 employees employees.
Where is NeuroSense Therapeutics's based?
NeuroSense Therapeutics is based in Cambridge, Massachusetts, United States.
Is NeuroSense Therapeutics publicly listed?
Yes. NeuroSense Therapeutics is a publicly traded company.
How can I contact NeuroSense Therapeutics's investor relations team?
You can reach NeuroSense Therapeutics’s investor relations department through the contact section on their official website or directly via the investor relations email listed in their latest SEC filings.
Find verified emails and phone numbers for professionals like those at
Up to 90% verified emails and mobile numbers, backed by weekly job-change alerts.
Find verified emails at this company
An email pattern tells you the format. It does not tell you who works there now or whether an address still delivers. Scalelist returns verified contacts, checked at the point you build the list.